Circumvention of multidrug resistance in genitourinary tumors

International Journal of Urology

Volumn 5, Issue 1, 1998, Pages 1-15

  Van Brussel, Jérôme P ^a   Mickisch, Gerald H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Circumvention; Modulators; Multidrug resistance; Prostate cancer; Renal cell cancer; Review; Testicular cancer

Indexed keywords

GLYCOPROTEIN P; PROTEIN BCL 2;

GLUTATHIONE METABOLISM; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; UROGENITAL TRACT TUMOR;

EID: 0031882511     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1998.tb00226.x     Document Type: Review

References (109)

1. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970; 30:1174-1184.
2. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
3. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-1654.
4. Morrow CS, Cowan KH. Glutathione S-transferases and drug resistance. Cancer Cells 1990;2:15-22.
5. Beck WT. Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev 1990;17:11-20.
6. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995; 9:451-473.
7. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
8. Tsuruo T, Iida H,Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-1972.
9. Ford JM. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 1996;32A:991-1001.
10. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42:155-199.
11. Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991;88:547-551.
12. Mickisch GH, Aksentijevich I, Schoenlein PV, Goldstein LJ, Galski H, Stahle C, Sachs DH, Pastan I, Gottesman MM. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 1992;79:1087-1093.
13. Mickisch GH, Schröder FH. From laboratory expertise to clinical practice: multidrug-resistance-based gene therapy becomes available for urologists. World J Urol 1994; 12:104-111.
14. Ohkawa K, Hatano T, Yamada K, Joh K, Takada K, Tsukada Y, Matsuda M. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res 1993;53:4238-4242.
15. Mickisch GH, Rahman A, Pastan I, Gottesman MM. Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin. J Natl Cancer Inst 1992; 84:804-805.
16. Iwahashi T, Okochi E, Ariyoshi K, Watabe H, Amann E, Mori S, Tsuruo T, Ono K. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res 1993;53:5475-5482.
17. Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E, Riggs CW, Komschlies K, Wiltrout RH, Tsuruo T, Pastan I, Gottesman MM, Longo DL. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 1991;83:1386-1391.
18. Rittmann-Grauer LS,Yong MA, Sanders V, Mackensen DG. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res 1992;52:1810-1816.
19. Mickisch GH, Pai LH, Gottesman MM, Pastan I. Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice. Cancer Res 1992;52:4427-4432.
20. Ihnat MA, Lariviere JP, Warren AJ, La Ronde N, Blaxall JRN, Pierre KM,Turpie BW, J. W. H. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin Cancer Res 1997;3: 1339-1346.
21. Campos L, Sabido O, Rouault JP, Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994;84:595-600.
22. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994;4:71-79.
23. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
24. Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman MM. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 1989;81:844-849.
25. KakehiY, Kanamaru H,Yoshida O, Ohkubo H, Nakanishi S, Gottesman MM, Pastan I. Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 1988;139:862-865.
26. Bak M Jr, Efferth T, Mickisch G, Mattern J, Volm M. Detection of drug resistance and P-glycoprotein in human renal cell carcinomas. Eur Urol 1990;17:72-75.
27. Volm M, Pommerenke EW, Efferth T, Lohrke H, Mattern J. Circumvention of multi-drug resistance in human kidney and kidney carcinoma in vitro. Cancer 1991;67: 2484-2489.
28. Scheltema JM, Romijn JC, Van Steenbrugge GJ, Beck WT, Schröder FH, Mickisch GH. Decreased levels of topoisomerase IIα in human renal cell carcinoma cell lines resistant to etoposide. J Cancer Res Clin Oncol 1997;123:546-554.
29. Mickisch GH, Roehrich K, Koessig J, Forster S,Tschada RK, Alken PM. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 1990;144:755-759.
30. Mickisch GH, Kossig J, Keilhauer G, Schlick E, Tschada RK, Alken PM. Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res 1990;50:3670-3674.
31. Glover D, Trump D, Kvols L, Elson P, Vogl S. Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys 1986;12:1405-1408.
32. Gehling U, Weimar C, Schuler U, Rathgeb R, Ehninger G, Schumacher K, Haveman K. A pilot study with dexniguldipine and doxorubicin in patients with metastatic hypernephroma. Onkologie 1993;16:25.
33. Law TM, Mencel P, Motzer RJ. Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drugs 1994;12:323-325.
34. Presant CA, Kennedy P, Wiseman C, Gala K, Smith JD, Bouzaglou A, Farbstein M, Multhauf P, Bertrand M, Green L, Opfell R, Chan C, Staples R, Chang F-F, Koehler S, Carr B. Pilot phase II trial of amphotericin B and CCNU in renal and colorectal carcinomas. Eur J Cancer Clin Oncol 1986;22:329-330.
35. Toffoli G, Sorio R, Gigante M, Corona G, Galligioni E, Boiocchi M. Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. Br J Cancer 1997;75:715-721.
36. Rodenburg CJ, Nooter K, Herweijer H, Seynaeve C, Oosterom R, Stoter G, Verweij J. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 1991;2:305-306.
37. Warner E, Tobe SW, Andrulis IL, Pei Y, Trachtenberg J, Skorecki KL. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am J Clin Oncol 1995;18:251-256.
38. Schwartsmann G, Medina de Cunha F, Silveira LA, Salgado G, Thereza MS, Vinholes J, Preger P, Segal F. Phase II trial of vinblastine plus nifedipine (VN) in patients with advanced renal cell carcinoma (RCC). Brazilian Oncology Trials Group. Ann Oncol 1991;2:443.
39. Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendeninn NJ, Wilding G. A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Invest New Drugs 1994;12:137-141.
40. Murphy BR, Rynard SM, Pennington KL, Grosh W, Loehrer PJ. A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study. Am J Clin Oncol 1994;17:10-13.
41. Agarwala SS, Bahnson RR, Wilson JW, Szumowski J, Ernstoff MS. Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma. A phase I study. Am J Clin Oncol 1995;18: 211-215.
42. Kakehi Y, Yoshida O, Segawa T, Kanematsu A, Hiura M, Shichiri Y, Arai Y. Intraarterial chemotherapy for metastatic renal cell carcinomas: combination with MDR-overcoming agents. Hinyokika Kiyo (Acta Urol Jpn) 1994;40:925-929.
43. Overmayer B, Fox K, Tomaszewski Jea. A phase II trial of R-verapamil and infusional vinblastine (velban) in advanced renal cell carcinoma (RCC). Proc Amer Soc Clin Oncol 1993;12:251.
44. Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, JP OB. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995;13:1958-1965.
45. Mickisch GH, Noordzij MA, van der Gaast A, Gebreamlack P, Kohrmann KU, Mogler-Drautz E, Kupper H, Schröder FH. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 1995;121:11-16.
46. Mickisch GH, Noordzij MA, Alken PM, Kupper H, Schröder FH. Sequentially designed phase II study of vinblastine and dexverapamil/vinblastine in metastatic renal cancer. Br J Urol 1997;119:464.
47. Scher HI. Systemic chemotherapy in regionally advanced bladder cancer. Theoretical considerations and results. Urol Clin North Am 1992;19:747-759.
48. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990;2:35-43.
49. Kotoh S, Naito S, Yokomizo A, Kumazawa J, Asakuno K, Kohno K, Kuwano M. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res 1994;54:3248-3252.
50. Ahn H, Lee E, Kim K, Lee C. Effect of glutathione and its related enzymes on chemosensitivity of renal cell carcinoma and bladder carcinoma cell lines. J Urol 1994; 151:263-267.
51. Giralt M, Lafuente A, Pujol F, Mallol J. Enhanced glutathione S-transferase activity and glutathione content in human bladder cancer. Followup study: influence of smoking. J Urol 1993;149:1452-1454.
52. Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M, Kumazawa J. Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J Urol 1997;157:1054-1058.
53. Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 1994;54:5255-5257.
54. Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SP, Kuwano M. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 1995;71: 907-913.
55. Nakagawa M, Emoto A, Nasu N, Hanada T, Kuwano M, Cole SP, Nomura Y. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 1997;157:1260-1265.
56. Pu YS, Tsai TC, Cheng AL, Tsai CY, Tseng NF, Su IJ, Hsieh CY, Lai MK. Expression of MDR-1 gene in transitional cell carcinoma and its correlation with chemotherapy response. J Urol 1996;156:271-275.
57. Long JP Jr, Prout GR Jr, Wong YK, Lin CW. The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent. J Urol 1990;143:1053-1056.
58. Kimiya K, Naito S, Soejima T, Sakamoto N, Kotoh S, Kumazawa J, Tsuruo T. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. J Urol 1992;148:441-445.
59. Duffy PM, Hayes MC, Cooper A, Smart CJ. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model. Br J Urol 1996;77:819-823.
60. Duffy PM, Hayes MC, Gatrell SK, Cooper A, Smart CJ. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study. Br J Urol 1996;77:824-829.
61. Park J, Shinohara N, Liebert M, Noto L, Flint A, Grossman HB. P-glycoprotein expression in bladder cancer. J Urol 1994;151:43-46.
62. Yoshimoto J, Saegusa M, Ochi J, Hara M, Akagi T, Obama T, Matsumura Y, Ohmori H, Tanahashi T. Intravesical chemotherapy of adriamycin and verapamil in patients with recurrent superficial bladder cancer: preliminary report. Gan To Kagaku Ryoho (Cancer Chemo) 1987;14: 1950-1952.
63. Tsushima T, Ohmori H, Ohi Y, Shirahama T, Kawahara M, Matsumura Y, Ohashi Y. Intravesical instillation chemotherapy of adriamycin with or without verapamil for the treatment of superficial bladder cancer: the final results of a collaborative randomized trial. Cancer Chemother Pharmacol 1994;35:S69-75.
64. Naito S, Kimiya K, Ueda T, Kumazawa J, Omoto T, Osada Y, Iguchi A, Ariyoshi A, Sagiyama K. Intravesical therapy with adriamycin plus verapamil in patients with superficial bladder cancer: a pilot study. Urol Int 1992; 48:270-273.
65. Naito S, Ueda T, Kotoh S, Iguchi A, Sagiyama K, Hiratsuka Y, Osada Y, Ariyoshi A, Omoto T, Kumazawa J. Prophylactic intravesical chemotherapy with adriamycin plus verapamil for primary superficial bladder cancer: preliminary results.The Kyushu University Urological Oncology Group. Cancer Chemother Pharmacol 1994;35: S76-80.
66. Lukkarinen O, Paul C, Hellstrom P, Kontturi M, Nurmi M, Puntala P, Ottelin J, Tammela T, Tidefeldt U. Intravesical epirubicin with and without verapamil for the prophylaxis of superficial bladder tumours. Scand J Urol Nephrol 1991;25:25-28.
67. Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 1994;74:2546-2554.
68. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992;84:1811-1816.
69. Pu YS, Hsieh TS, Cheng AL, Tseng NF, Su IJ, Hsieh CY, Lai MK, Tsai TC. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy. Br J Urol 1996;77:76-85.
70. See WA, Xia Q. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst 1992;84:510-515.
71. Scott WW, Menon M, Walsh PC. Hormonal therapy of prostatic cancer. Cancer 1980;45:1929-1936.
72. Scher HI, Sternberg CN. Chemotherapy of urologic malignancies. Semin Urol 198;3:239-280.
73. Isaacs JT. Introduction: survey of outstanding problems in the management of prostatic cancer. Cancer Surv 1991;11:1-3.
74. Schröder FH. Endocrine therapy: where do we stand and where are we going? Cancer Surv 1991;11:177-194.
75. Mahler C, Denis L. Management of relapsing disease in prostate cancer. Cancer 1992;70:329-334.
76. Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 1988;15:371-389.
77. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71:1098-1109.
78. Nemoto R, Hattori K, Uchida K, Shimazui T, Nishijima Y, Koiso K, Harada M. S-phase fraction of human prostate adenocarcinoma studied with in vivo bromodeoxyuridine labeling. Cancer 1990;66:509-514.
79. Theyer G, Schirmbock M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 1993;150:1544-1547.
80. Dunning WF. Prostate cancer in rat. Natl Cancer Inst Monogr 1963;12:351-369.
81. Bashir I, Sikora K, Abel P, Foster CS. Establishment and in vivo characterization of multidrug-resistant dunning R3327 rat prostate-carcinoma cell-lines. Int J Cancer 1994;57:719-726.
82. Mickisch GH, Pai LH, Siegsmund M, Campain J, Gottesman MM, Pastan I. Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice. J Urol 1993;149:174-178.
83. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-124.
84. Sugawara I, Akiyama S, Scheper RJ, Itoyama S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 1997;112:23-31.
85. Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 1994;151:485-491.
86. Tasaki Y, Nakagawa M, Ogata J, Kiue A, Tanimura H, Kuwano M, Nomura Y. Reversal by a dihydropyridine derivative of non-P-glycoprotein-mediated multidrug resistance in etoposide-resistant human prostatic cancer cell line. J Urol 1995;154:1210-1216.
87. Nooter K, Westerman AM, Flens MJ, Zaman GJR, Scheper RJ, Van Wingerden KE, Burger H, Oostrom R, Boersma T, Sonneveld P, Gratama JW, Kok T, Eggermont AMM, Bosman FT, Stoter G. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995;1:1301-1309.
88. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91: 11733-11737.
89. Murray GI, Taylor VE, McKay JA, Weaver RJ, Ewen SW, Melvin WT, Burke MD. The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J Pathol 1995;177:147-152.
90. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-1576.
91. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995,55:735-738.
92. Mittelman A, Shukla SK, Welvaart K, Murphy GP. Oral estramustine phosphate (NSC-89199) in the treatment of advanced (stage D) carcinoma of the prostate. Cancer Chemother Rep 1975,59:219-223.
93. Pienta KJ, Lehr JE. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 1993,149:1622-1625.
94. Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst 1994,86:688-694.
95. Mani S, Vogelzang NJ. Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted? Hematol Oncol Clin North Am 1996;10:749-768.
96. Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 1996;88:794-801.
97. Mydlo JH, Michaeli J, Heston WD, Fair WR. Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. Prostate 1988;13:241-247.
98. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, Hickson ID. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991;51:6592-6595.
99. Fernandes DJ, Danks MK, Beck WT. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry 1990;29:4235-4241.
100. Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994;54:539-546.
101. Li CJ, Wang C, Pardee AB. Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res 1995;55:3712-3715.
102. Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR, Wilding G, Boothman DA. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res 1995;55:3706-3711.
103. Hudes GR, Kosierowski R, Greenberg R, Ramsey HE, Fox SC, Ozols RF, McAleer CA, Giantonio BJ. Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest New Drugs 1995;13:235-240.
104. Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764.
105. Katagiri A, Tomita Y, Nishiyama T, Kimura M, Sato S. Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis cancer. Br J Cancer 1993;68:125-129.
106. Masters JR,Thomas R, Hall AG, Hogarth L, Matheson EC, Cattan AR, Lohrer H. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 1996;32A:1248-1253.
107. Eid H, Institoris E, Bodrogi I, Bak M. Metallothionein expression as a marker of therapeutic sensitivity in the early stages of testicular cancer. Orv Hetil 1997;138:135-139.
108. Eid H, Van der Looij M, Institoris E, Geczi L, Bodrogi I, Olah E, Bak M. Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer? Anticancer Res 1997;17:2663-2669.
109. Bokemeyer C, Dunn T, Harstrick A, Lerch T, Poliwoda H, Schmoll HJ. Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicularcancer cell lines differing in their sensitivity to standard agents. Int J Cancer 1994;56:452-456.